Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,377 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,981 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00150995 | Tetrathiomolybdate in Hormone Refractory Prostate Cancer | completed | Phase 2 | 19 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 21, 2015 | clinicaltrials |
| NCT00151047 | Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer | completed | Phase 2 | 15 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 21, 2015 | clinicaltrials |
| NCT00151060 | Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate | completed | Phase 2 | 28 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 21, 2015 | clinicaltrials |
| NCT00134355 | Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer | completed | Phase 2 | 5 | University of Michigan Rogel Cancer CenterOTHER | 0 | Jan 19, 2015 | clinicaltrials |
| NCT00913263 | An Efficacy and Safety Study With Licroca Depot, a Controlled Release Product, Injected Into the Prostate(2-HOF) | completed | Phase 1 / Phase 2 | 24 | Lidds ABINDUSTRY | 1 | Jan 19, 2015 | clinicaltrials |
| NCT02065323 | A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT | withdrawn | Phase 2 | 0 | Oscar Goodman, Jr.OTHER | 1 | Jan 19, 2015 | clinicaltrials |
| NCT02342054 | Single Fraction Real-time High-Dose-Rate Brachytherapy in Patients With Low and Intermediate Risk Prostate Cancer(SINFRA_PROST) | unknown | Phase 2 | 49 | Hospital de CrucesOTHER | 1 | Jan 19, 2015 | clinicaltrials |
| NCT00666666 | R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Dec 18, 2014 | clinicaltrials |
| NCT01469338 | Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel | terminated | Phase 2 | 9 | University of Southern CaliforniaOTHER | 1 | Nov 24, 2014 | clinicaltrials |
| NCT01531205 | Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA | terminated | Phase 2 | 2 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 5, 2014 | clinicaltrials |
| NCT00753220 | Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer(CRITICAL) | terminated | Phase 1 / Phase 2 | 7 | Bostwick LaboratoriesINDUSTRY | 1 | Nov 4, 2014 | clinicaltrials |
| NCT00918385 | Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer(ARS) | terminated | Phase 2 | 57 | Duke UniversityOTHER | 1 | Oct 29, 2014 | clinicaltrials |
| NCT00751205 | Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC) | completed | Phase 2 | 150 | BayerINDUSTRY | 6 | Oct 28, 2014 | clinicaltrials |
| NCT00683475 | A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer | completed | Phase 2 | 138 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 16, 2014 | clinicaltrials |
| NCT01009736 | Effects of Tomato-Soy Juice on Biomarkers in Patients With Prostate Cancer Undergoing Prostatectomy | completed | Phase 1 / Phase 2 | 60 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Oct 16, 2014 | clinicaltrials |
| NCT01020305 | Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 5 | Sandy SrinivasOTHER | 1 | Oct 13, 2014 | clinicaltrials |
| NCT02258087 | HDR vs LDR Brachytherapy as Monotherapy in the Treatment of Localized Prostate Cancer.(PROMOBRA) | unknown | Phase 2 / Phase 3 | 50 | National Institute of Oncology, HungaryOTHER | 1 | Oct 7, 2014 | clinicaltrials |
| NCT00103194 | Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer | completed | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2014 | clinicaltrials |
| NCT01704027 | Safety Study of Pelvic and Prostatic SIB-IMRT With Long-term Androgen Deprivation for High Risk Localized Prostate Cancer | terminated | Phase 2 | 28 | Centre Georges Francois LeclercOTHER | 1 | Sep 18, 2014 | clinicaltrials |
| NCT00323882 | Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer | completed | Phase 1 / Phase 2 | 75 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 28, 2014 | clinicaltrials |
| NCT00385827 | A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC) | terminated | Phase 2 | 106 | Centocor, Inc.INDUSTRY | 7 | Aug 20, 2014 | clinicaltrials |
| NCT00476645 | Fulvestrant in Hormone Refractory Prostate Cancer | completed | Phase 2 | 10 | Stanford UniversityOTHER | 1 | Aug 5, 2014 | clinicaltrials |
| NCT00672594 | Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy | completed | Phase 2 | 30 | Duke UniversityOTHER | 1 | Aug 4, 2014 | clinicaltrials |
| NCT00004050 | Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer | terminated | Phase 2 | 13 | VicalINDUSTRY | 1 | Jul 29, 2014 | clinicaltrials |
| NCT00005072 | Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer | terminated | Phase 1 / Phase 2 | 25 | VicalINDUSTRY | 1 | Jul 29, 2014 | clinicaltrials |
| NCT01424930 | A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 25 | Janssen-Ortho Inc., CanadaINDUSTRY | 1 | Jul 25, 2014 | clinicaltrials |
| NCT02054793 | Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC) | withdrawn | Phase 1 / Phase 2 | 0 | Emmanuel Antonarakis, MDOTHER | 1 | Jul 23, 2014 | clinicaltrials |
| NCT00349557 | Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer | completed | Phase 2 | 18 | Benaroya Research InstituteOTHER | 1 | Jul 16, 2014 | clinicaltrials |
| NCT00278993 | Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy | completed | Phase 2 | 108 | Eisai Inc.INDUSTRY | 1 | Jul 14, 2014 | clinicaltrials |
| NCT00919035 | Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients | completed | Phase 2 | 21 | Oncology Specialists, S.C.OTHER | 1 | Jun 30, 2014 | clinicaltrials |
| NCT00459654 | A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer | completed | Phase 2 | 64 | BayerINDUSTRY | 2 | Jun 25, 2014 | clinicaltrials |
| NCT00337077 | Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 121 | National Cancer Institute (NCI)NIH | 1 | Jun 23, 2014 | clinicaltrials |
| NCT00515112 | Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer | terminated | Phase 2 | 6 | University of ChicagoOTHER | 1 | Jun 11, 2014 | clinicaltrials |
| NCT00390468 | Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00330161 | Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer | completed | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | May 26, 2014 | clinicaltrials |
| NCT02145494 | The SPARC Trial: Stereotactic Prostate Ablative Radiotherapy Using Cyberknife(SPARC) | unknown | Phase 2 | 20 | Royal Marsden NHS Foundation TrustOTHER | 1 | May 23, 2014 | clinicaltrials |
| NCT00183924 | Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy. | completed | Phase 2 | 20 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00176605 | Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer | completed | Phase 2 | 15 | Rutgers, The State University of New JerseyOTHER | 1 | May 20, 2014 | clinicaltrials |
| NCT01088529 | Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer | completed | Phase 2 | 66 | Cougar Biotechnology, Inc.INDUSTRY | 1 | May 15, 2014 | clinicaltrials |
| NCT00087139 | Ixabepilone in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 124 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
| NCT01483586 | Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer | terminated | Phase 2 | 90 | KangLaiTe USAINDUSTRY | 1 | Apr 14, 2014 | clinicaltrials |
| NCT00678015 | Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non Metastatic Recurrent Prostate Cancer | terminated | Phase 2 | 12 | University of California, San FranciscoOTHER | 1 | Apr 9, 2014 | clinicaltrials |
| NCT00072670 | A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer | completed | Phase 2 | 59 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 1 | Apr 8, 2014 | clinicaltrials |
| NCT00414388 | Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer | completed | Phase 1 / Phase 2 | 22 | Oncology Specialists, S.C.OTHER | 1 | Apr 7, 2014 | clinicaltrials |
| NCT00487721 | The Effect of High-dose Silybin-phytosome in Men With Prostate Cancer | completed | Phase 2 | 12 | University of Colorado, DenverOTHER | 1 | Mar 31, 2014 | clinicaltrials |
| NCT00439270 | Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer | completed | Phase 1 / Phase 2 | 49 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 28, 2014 | clinicaltrials |
| NCT00654186 | Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients | completed | Phase 2 | 32 | Oncology Specialists, S.C.OTHER | 1 | Mar 28, 2014 | clinicaltrials |
| NCT00859729 | Dose Finding Study of a DNA Vaccine Delivered With Intradermal Electroporation in Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 15 | Uppsala UniversityOTHER | 1 | Mar 17, 2014 | clinicaltrials |
| NCT00770848 | AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 162 | AmgenINDUSTRY | 0 | Mar 10, 2014 | clinicaltrials |
| NCT01338792 | Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer | completed | Phase 2 | 47 | University of Southern CaliforniaOTHER | 1 | Mar 10, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Jan 21, 2015source: clinicaltrials